		<div class="wpcnt">
			<div class="wpa">
				<span class="wpa-about">Advertisements</span>
				<div class="u top_amp">
							<amp-ad width="300" height="265"
		 type="pubmine"
		 data-siteid="111265417"
		 data-section="2">
		</amp-ad>
				</div>
			</div>
		</div><p>Having chemotherapy every two weeks, rather than three, can improve survival chances for women under 50 with breast cancer, new research suggests.</p>
<p>The two-weekly therapy doesn’t seem to increase a woman’s risk of treatment-induced early menopause, the researchers said, meaning young women would suffer no greater cost to their fertility.</p>
<p>The study, to be presented to the European Breast Cancer Conference in Amsterdam, analysed data from two large clinical trials that compared adjuvant chemotherapy given every two weeks, known as a “dose dense” regimen, or every three weeks – the standard interval.</p>
<p>A total of 3,305 patients were included in both studies, of whom 1,549 were pre-menopausal with an average age of 44.</p>
<p>The researchers found that the two-weekly chemotherapy significantly improved overall survival after 10 years by nearly a third compared with chemotherapy given at the standard interval of three weeks.</p>
<p>Dr Matteo Lambertini, a medical oncologist at the National Institute for Cancer Research in Genoa, Italy, will tell delegates: “The take-home message of our study is that dose-dense adjuvant chemotherapy is associated with a significant improvement in overall survival as compared to standard-interval chemotherapy in high-risk, pre-menopausal breast cancer patients.</p>
<p>“This is very important information for counselling young patients regarding the choice among the available adjuvant chemotherapy regimens.</p>
<p>“Chemotherapy remains a mainstay adjuvant treatment for the majority of young breast cancer patients, but its psychosocial impact can be substantial.”</p>
<p><a href="http://londonglossy.com/wp-content/uploads/2016/03/image-28.jpg" rel="attachment wp-att-87131"><img src="http://londonglossy.com/wp-content/uploads/2016/03/image-28-300x226.jpg" alt="image" width="300" height="226" class="alignright size-medium wp-image-87131" /></a></p>
<p>Katie Goates, senior research communications officer at Breast Cancer Now, said: “This promising study confirms that having chemotherapy every two weeks, rather than three, can improve the chance of survival for women with breast cancer under 50.</p>
<p>“Additionally, the findings reassuringly show that the increased survival seen with two-weekly chemotherapy doesn’t come at a greater cost to fertility, something that is incredibly important for young women considering their treatment options.</p>
<p>“However, the research also shows that two-weekly chemotherapy can increase the possibility of side-effects such as anaemia and muscle or bone pain.</p>
<p>“This serves as a critical reminder of the need to find treatments that improve both women’s chances of survival and their quality of life during treatment.”</p>
			<div style="padding-bottom:15px;" class="wordads-tag" data-slot-type="belowpost">
				<div id="atatags-dynamic-belowpost-68ed5e3d1d8d3">
					<script type="text/javascript">
						window.getAdSnippetCallback = function () {
							if ( false === ( window.isWatlV1 ?? false ) ) {
								// Use Aditude scripts.
								window.tudeMappings = window.tudeMappings || [];
								window.tudeMappings.push( {
									divId: 'atatags-dynamic-belowpost-68ed5e3d1d8d3',
									format: 'belowpost',
								} );
							}
						}

						if ( document.readyState === 'loading' ) {
							document.addEventListener( 'DOMContentLoaded', window.getAdSnippetCallback );
						} else {
							window.getAdSnippetCallback();
						}
					</script>
				</div>
			</div>
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
